Article Cited by others

ORIGINAL ARTICLE

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients

Wang Yue, Dai Bo, Ye Ding-Wei

Year : 2017| Volume: 19| Issue : 2 | Page no: 178-183

   This article has been cited by
 
1 Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel
Keisuke Ando,Shinichi Sakamoto,Nobushige Takeshita,Ayumi Fujimoto,Maihulan Maimaiti,Shinpei Saito,Pae Sanjyon,Yusuke Imamura,Nobuo Sato,Akira Komiya,Koichiro Akakura,Tomohiko Ichikawa
The Prostate. 2019;
[Pubmed]  [Google Scholar] [DOI]
2 Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
Yinghao Sun,Liping Xie,Xu Tao,Jørn S. Jakobsen,Weiqing Han,Per S. Sørensen,Xiao Feng Wang
Asian Journal of Urology. 2019;
[Pubmed]  [Google Scholar] [DOI]
3 Discordance between testosterone measurement methods in castrated prostate cancer patients
Mélanie Rouleau,Francis Lemire,Michel Déry,Benoît Thériault,Gabriel Dubois,Yves Fradet,Paul Toren,Chantal Guillemette,Louis Lacombe,Laurence Klotz,Fred Saad,Dominique Guérette,Frédéric Pouliot
Endocrine Connections. 2019; : 132
[Pubmed]  [Google Scholar] [DOI]
4 Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis
Mélanie Claps,Fausto Petrelli,Orazio Caffo,Vito Amoroso,Elisa Roca,Alessandra Mosca,Francesca Maines,Sandro Barni,Alfredo Berruti
Clinical Genitourinary Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Sex steroids in the tumor microenvironment and prostate cancer progression
Clovis Boibessot,Paul Toren
Endocrine-Related Cancer. 2018; 25(3): R179
[Pubmed]  [Google Scholar] [DOI]

 

Read this article